KCNIP4 encodes a regulatory subunit of Kv4-type voltage-gated A-type potassium channels, modulating channel density, inactivation kinetics, and recovery from inactivation in a calcium-dependent manner. It regulates both KCND2 and KCND3 currents, with certain isoforms retaining KCND3 in the endoplasmic reticulum and suppressing its surface expression. Beyond its canonical channel-regulatory role, KCNIP4 has emerged as a psychiatric and neurological risk locus. Genome-wide association studies identified KCNIP4 variants associated with asthma and airway hyperresponsiveness 1, adult attention-deficit/hyperactivity disorder and personality disorders 2, and post-traumatic stress disorder in the dorsolateral prefrontal cortex 3. Recent evidence suggests that inhibition of miR-3068-3p increases KCNIP4 expression and enhances A-type potassium current density, conferring neuroprotection against glutamate-induced excitotoxicity in ischemic stroke models 4. Additionally, KCNIP4 variants associate with angiotensin-converting enzyme inhibitor-induced cough, a common pharmacological side effect 5. Clinically, KCNIP4 represents a potential therapeutic target in neuropsychiatric and neurodegenerative disorders. The miR-3068-3p/KCNIP4 axis may offer a novel avenue for stroke intervention, and KCNIP4-modulating approaches could address ADHD and trauma-related psychiatric conditions, though functional validation studies remain necessary.